Treatment for unresectable gastric cancer.
10.5124/jkma.2015.58.3.209
- Author:
Tae Yong KIM
1
;
Do Youn OH
;
Yung Jue BANG
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. bangyj@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Stomach neoplasms;
Neoplasm metastasis;
Drug therapy
- MeSH:
Drug Therapy;
Humans;
Neoplasm Metastasis;
Platinum;
Stomach Neoplasms*;
Trastuzumab
- From:Journal of the Korean Medical Association
2015;58(3):209-215
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Systemic chemotherapy is the cornerstone of treatment for patients with advanced gastric cancer. The combination of fluoropyrimidine and platinum is the most widely used first-line treatment worldwide. In patients with HER2-positive gastric cancer, the combination of trastuzumab (an anti-HER2 monoclonal antibody) and chemotherapy is the standard-of-care. Second-line chemotherapy can also prolong patients' survival after progression; treatment options include cytotoxic chemotherapy (paclitaxel, docetaxel or irinotecan) and/or ramucirumab (an anti-VEGFR2 monoclonal antibody). A number of new targeted-agents are currently being studied, and more personalized approaches will be realized in the near future.
